Background. Knowledge of the risk factors of individuals with an asymptomatic sexually transmitted infection (STI) is essential for implementation of targeted STI screening strategies.
Rates of sexually transmitted infections (STIs) are rising in men who have sex with men (MSM) and individuals with human immunodeficiency virus (HIV) infection [1] [2] [3] [4] [5] . Patients with a primary HIV infection treated with early antiretroviral therapy (ART) represent a highly sexually active population and contribute substantially to this epidemic [6, 7] . Recognizing the high prevalence of STIs in the HIV-infected and HIVuninfected MSM population, the Centers for Disease Control and Prevention recommends routine laboratory screening for common STIs (ie, syphilis, gonorrhea, chlamydia) at least annually for sexually active MSM and a more frequent STI screening (ie, at 3-6-month intervals) for MSM who have multiple or anonymous partners [2] .
During recent years it has been recognized that STIs commonly present as asymptomatic, predominantly affect MSM, and may occur in multiple anatomic sites [4, [8] [9] [10] [11] [12] ]. An intensive 3-site screening (ie, rectal, pharyngeal, urethral) is therefore needed to detect asymptomatic STIs [13] appropriately. The rationale to direct efforts into diagnosing and treating asymptomatic STIs include (1) the identification of transmitter pools and the reduction of onward transmission, (2) the prevention of disseminated infection, (3) the identification of other STIs through partner notification, and (4) the prevention of the emergence of resistance as the oropharyngeal niche provides an enabling environment for horizontal transfer of genetic material from commensal Neisseria sp. and other bacterial species to Neisseria gonorrhoeae (20) [14] .
A recently published mathematical model [15] showed that the introduction of a routine STI screening every 6 months could reduce the incidence of Chlamydia trachomatis and HIV infection by 15% and 4%, respectively. However, 3-site screening at 3-6-month intervals is both time and cost consuming [16] .
Given the high burden of STIs, especially in HIV-infected MSM, and the challenges to identify them accurately, better knowledge of the characteristics and risk factors of patients with STIs, specifically asymptomatic STIs, is crucial to better guiding healthcare providers on whom to screen. In this regard, data are particularly scarce concerning HIV-infected individuals whose initial diagnosis was of acute or recent infection. Understanding the risk profile and behavioral attitudes associated with STI acquisition could help identify individuals in need of regular and intensified STI screening. Here we report on the characteristics of 214 HIV-infected predominantly MSM enrolled in the Zurich Primary HIV-Infection (ZPHI) study and the risk factors associated with STI detection in this population.
METHODS

Study Population
All patients had a documented primary HIV infection and are enrolled in the ZPHI, an open-label, nonrandomized, observational, single-center study (ClinicalTrials.gov, ID NCT00537966) [17] . The ethics committee of the Canton of Zurich approved the study protocol, and written informed consent was obtained from all patients. Acute or recent primary HIV infection was confirmed in all patients, as published elsewhere [17] [18] [19] . Acute HIV infection was defined as acute retroviral syndrome (ARS), negative or indeterminate HIV line immunoassay results in the presence of positive p24-antigen, and/or detectable HIV-1 RNA, or as a documented seroconversion with or without symptoms during the past 90 days. Recent infection was defined as possible ARS, positive HIV Line Immunoassay results, detectable HIV-RNA, and a negative HIV glycoprotein 120 avidity or detuned assay result, or as a documented acute HIV-1 infection but with referral to our center >90 but <180 days after the presumed date of infection.
All patients considered in this study are also participants in the Swiss HIV Cohort Study (SHCS) (www.shcs.ch) [20] . The SHCS is a prospective cohort with ongoing enrollment for HIV-infected individuals in Switzerland that started in 1988. Clinical, laboratory, and sociodemographic information is collected every 6 months, including information about sexual behavior. In addition, detailed treatment history is kept for all patients.
Data Collection
Between 1 June 2015 and 31 January 2017 we offered regular STI screenings to all patients from the ZPHI study who had a clinical visit. Patients had to be screened at least once to be included in the analysis. They were then also asked to complete a behavioral questionnaire that assessed the sexual behavior and symptoms related to a possible STI in the preceding 3 months (Supplementary Material). From June 2015 to June 2016, we performed separate polymerase chain reaction (PCR) tests for each anatomic site to determine the sites of infection. To reduce costs, the sampling procedure was simplified to a pooled STI screening from July 2016 to January 2017.
Laboratory Tests
Swabs obtained from the urethra, rectum and pharynx were tested by PCR for C. trachomatis and N. gonorrhoeae. Blood was tested for syphilis by Treponema-pallidum-Particleagglutination (TPPA), and VDRL and/or rapid plasma reagin tests were done in the event of a positive TPPA result. Patients were also tested yearly for anti-hepatitis C virus (HCV) immunoglobulin G. In patients presenting with elevated transaminase levels, with >50 U/L as the upper limit of a normal value, blood samples were also tested for hepatitis C by PCR. For detailed testing information, see Supplemetary box 1. For specific treatment see Supplemetary box 2.
Statistical Analysis
Statistical analysis was performed using R software, version 3.3.2. Bivariate P values were calculated using the Fisher exact test for categorical variables and the Wilcoxon test for continuous variables. Bivariate P values were adjusted for multiple comparisons using the Benjamini-Hochberg procedure. For multivariable analysis, with the outcome of STI diagnosis during any of the screening visits, a generalized linear mixed model logistic regression was used with a per-patient random intercept. Apart from age at diagnosis and CD4 cell count, which were included a priori, variables that were significant in the bivariate analysis (Benjamini-Hochberg P < .05) were included in the multivariable model, if not strongly collinear with another independent variable. Square root transformation was performed on the CD4 cell counts to fulfill model assumptions [21] . The Cox proportional hazard model was used for the prospective subsample with a negative baseline, with the same selection strategy for variables.
RESULTS
Visits, Patients, and Period Prevalence of STI
During the study period, 623 follow-up visits from 214 patients occurred with a median of 3 visits per patient (range, 1-4 visits); 174 of 214 patients (81%) agreed to be screened at least once, accounting for 334 visits ( Figure 1 ) with a valid STI screening. In total, 79 STIs were detected in 58 patients during 71 visits, reflecting a high period prevalence of 33.3% (58 of 174; 95% confidence interval [CI], 26.4%-40.9%). Even if it is assumed that all 40 untested patients had no STIs, this would still imply a high period prevalence of 27.1% (58 of 214; 21.3%-33.6%). In 8 visits, >1 STI was detected in the same patient. The most prevalent reported reason for the 40 patients' study nonparticipation was a reported belief that their risky behavior was insufficient to warrant screening ( Figure 1 ).
The most common STIs were chlamydia (50.6%; 40 of 79), gonorrhea (25.3%; 20 of 79), and syphilis (19%; 15 of 79) ( Table 1 ). The stage of syphilis infection included stage 1 (n = 7; 47%), stage 2 (n = 3; 20%), early latent (n = 4; 27%), and neurosyphilis (n = 1; 6%). A large fraction (of the detected STIs 65.8%; 52 of 79) were asymptomatic. For both chlamydia and gonorrhea, the rectum was the most prevalent anatomic site of infection, accounting for 62.5% (20 of 32; 8 unknown owing to pooled testing) and 53.3% (8 of 15; 5 unknown owing to pooled testing), respectively (Supplementary Table S1 ). The 3 detected HCV infections were considered incident infections because all 3 individuals had a prior negative HCV antibody test recorded in the SHCS database, presented with recently elevated liver transaminase levels, and reported risky sexual behavior and/or drug use in the preceding months.
HIV Diagnosis During Primary Infection and Subsequent Risky Sexual Behavior
First, we examined whether presentation with a documented primary HIV infection was associated with a higher rate of later risky sexual behavior, compared with HIV diagnosis during the chronic phase. We compared 169 MSM ZPHI patients who initially presented with documented primary HIV infection and were offered STI screening in this study with 5105 MSM from the SHCS without a documented primary HIV infection. The outcome variable was reported condomless sex with an occasional partner at least once after diagnosis of HIV infection. After adjustment for age at diagnosis, year of diagnosis, and first CD4 cell count, diagnosis of a primary HIV infection was associated with a 5-fold higher odds for later risky sexual behavior, compared with diagnosis during the chronic phase (adjusted odds ratio [OR], 5.58; 95% CI, 3.68-8.8) ( Table 2) .
Factors Correlating With STI Detection
Only 1 STI was detected in the heterosexual risk group, with the remaining 98.6% (70 of 71) of visits with an STI belonging to Table 3) . In a multivariable model restricted to MSM, the number of years since HIV diagnosis (OR, 0.87; 95% CI, .8-.96) and √CD4 cell count (0.93; .87-.99) were negatively associated with the odds of having a positive STI test result (Figure 2A ). On the other hand, engaging in insertive (OR, 6.48; 95% CI, 1.14-36.76) or both insertive and receptive (4.61; 1.01-20.96) anal intercourse in the last 3 months, reporting STI symptoms (3.4; 1.68-6.89,) and reporting condomless sex (2.06; 91.14-3.74) were all positively correlated with the odds for a positive screening result.
Incidence Rate and Survival Analysis
Seventy-three patients were screened more than once and had a first negative screening result, which served as a baseline for the incidence analysis. Overall, 21 patients had ≥1 incident STI during a total of 37.2 person-years, which corresponds to an incidence density rate of 56 (95% CI, 35- Table S2 ). In a multivariable Cox proportional hazard model restricted to MSM only, the hazard of an incident STI increased with the presence of STI symptoms (hazard ratio, 3.03; 95% CI, 1.17-7.84; P = .02) and any recent drug use (2.63; 1-6.9: P = .049) ( Figure 2B) .
Finally, considering the above-mentioned finding that any recent drug use was associated with STI risk, we explored data about use of specific substances ( Table 4) . None of the examined MSM reported intravenous heroin or cocaine use. However, a strong bivariate association was found between incident STI and recent use of noninjectable cocaine, cannabis, and other noninjectable drugs (as a group), (adjusted P = .005, .01, and .006, respectively). More specifically, recent use of ecstasy or gamma-hydroxybutyric acid was significantly associated with an incident STI, with rates of 28.6% (6 of 21) versus 0 of 47 (P = .003), and 19% (4 of 21) versus 0 of 47 (P = .01), respectively.
DISCUSSION
In this prospective analysis of mainly Swiss MSM with a prior diagnosis of primary HIV infection treated with suppressive ART during the study, we found a very high period prevalence and incidence rate of STIs. In line with the literature, the majority of the detected STIs were asymptomatic, and the most affected anatomic site was the rectum [1, 4, 8, 9, 11, 13, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . We identified 3 independent factors predictive of a positive STI screening result: (1) engaging in insertive or both insertive and receptive anal intercourse, (2) reporting STI symptoms, and (3) reporting condomless sex.
The STI period prevalence of 33% and the incidence rate of 61.6 per 100 person-years in our study is high compared with other studies in Western Europe. A study of HIV-infected MSM in the SHCS found an overall point STI prevalence of 20%, and another study from Germany reported a markedly lower STI prevalence of 15% in its MSM population [12, 23] .
The very high prevalence in our study could be explained by several factors. First, individuals initially diagnosed with primary HIV infection might constitute per se a high-risk population as suggested by our analysis of rates of risky sexual behavior in patients with a diagnosis of primary versus chronic HIV infection. Second, individuals receiving suppressive ART are considered noninfectious for their sexual partners in terms of HIV, which might result in risk-compensation behavior and thus higher risk for contracting bacterial STIs and hepatitis C. In line with this assumption, a 2-fold increase in the syphilis incidence was observed in the SHCS after 2008, the year the so-called Swiss statement was introduced, which declared that HIV-infected persons receiving effective HIV treatment are not at risk of transmitting HIV through sexual contact [5, 35, 36] . The fact that 3 individuals were identified with acute HCV infection reflects the current HCV epidemic affecting MSM, predominantly those coinfected with HIV, and it emphasizes the need for systematic HCV screening in the affected population [37] . No. of symptoms, median ( In line with the literature, the majority (66%) of our patients with an STI did not report any symptoms at presentation and immediately before STI testing. In recent years, a plethora of data have been published supporting the strategy to screen asymptomatic sexually active individuals for STIs, especially in the MSM population [4, 8, 9, 11, 13, 23, 28, 30] . Because up to 90% of STIs are asymptomatic [23] , a symptom-based testing approach would fail to both accurately detect STIs and interrupt the transmission chain by prompt treatment. On the other hand, and as expected, symptoms were highly predictive of an STI in this high-risk population in the minority of cases in which they were reported.
In our multivariable model restricted to MSM, a longer time since HIV diagnosis and a higher √CD4 cell count were associated with lower odds of a positive STI screening result. The negative-age-adjusted-association with the duration of HIV infection might indicate that individuals in whom HIV infection was diagnosed more recently have a higher sensitivity to safe-sex fatigue or a higher rate of STI treatment optimism [38] than those whose HIV infection was diagnosed in previous years. However, this hypothesis should be further investigated in future behavioral studies. The negative association of an STI with √CD4 cell count probably has no clinical significance because the median CD4 cell count even among patients with an STI was relatively high (605/μL). Moreover, a recent study with a large sample size did not find an association of √CD4 cell count with the hazard of contracting syphilis [5] .
We found that engaging in anal intercourse, reporting condomless sex, and also reporting any recent drug use for incident STI, predicted a positive STI screening result. All of these variables are a proxy for risky sexual behavior and associated with a higher incidence of STIs in several studies [5, 13, 23, 30, 34] . In line with the literature [13, 25] , we found a strong association between incident STI and recent use of noninjectable drugs, specifically noninjectable cocaine, psychotropic drugs, and cannabis. Although only 1 MSM reported intravenous drug use, we believe that some underreporting cannot be ruled out in our study population. Even though the use of certain drugs such as methamphetamine, mephedrone, and gamma-hydroxybutyrate/gamma-butyrolactone in combination with sex-often referred to as "chemsex"-was initially occurring predominantly in London [39] , similar scenes have also set up in other European cities with an established gay culture, including Switzerland [40] . Recently, local clusters of crystal methamphetamine use in rural and urban areas in Switzerland have been reported [41] . Our study findings have several implications for clinical practice. First, a trimonthly STI screening can benefit MSM reporting sexually risky behavior and/or any recent drug use, regardless of symptoms. This is supported both by empirical data and by a modeling study of preexposure prophylaxis users showing that more intensive STI screening might substantially decrease the STI rate [42, 43] . Second, because most but not all diagnosed STIs affected the rectum, the STI screening should include all 3 anatomic sites: rectum, pharynx, and urethra. A pooled STI screening is a promising way to reduce costs and promote acceptance of this approach by health insurers. Third, because the presence of symptoms was highly predictive for a positive STI screening result in our study, symptoms and signs compatible with an STI should trigger the prompt initiation of STI testing. Finally, consultations should be used to promote safer sex practices, because suppressive ART does not replace condoms for protection from STIs in general. However, because all of our patients were counseled accordingly, the effect of additional counseling is questionable.
Our study has several strengths and limitations. One strength is that the prospective and longitudinal study design allowed us to calculate incidence rates. In addition, owing to the unique design of the SHCS and the ZPHI studies, we were able to test associations between STIs and a variety of risk and behavioral factors. One limitation of the study is that, because of the change from a 3-site to a pooled screening approach, we could not assess the exact site of the infection during the whole study. However, this had no implication for the treatment of the STI or for identification of risk factors associated with STI prevalence and incidence.
In conclusion, we found a very high prevalence of asymptomatic STIs in patients who initially presented with a primary HIV-1 infection, most of whom were treated with suppressive ART during the study. The significant associations of STIs with anal intercourse and the reporting of condomless sex or any recent drug use could help identify a subgroup of high-risk MSM and prioritize screening and resource allocations.
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